The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma and mantle cell lymphoma. Roche’s heritage in non-hodgkin lymphoma treatment Rituximab ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and FL grade 3B. The application is supported by data ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...